Jason Kolbert
Stock Analyst at Dawson James
(0.50)
# 2,968
Out of 4,479 analysts
28
Total ratings
46.15%
Success rate
-18.45%
Average return
Main Sectors:
20 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNXP Tonix Pharmaceuticals Holding | Initiates: Buy | $96 | $0.74 | +12,925.78% | 1 | Feb 28, 2024 | |
| BJDX Bluejay Diagnostics | Downgrades: Neutral | n/a | $0.65 | - | 2 | Aug 3, 2023 | |
| GOVX GeoVax Labs | Initiates: Buy | $60 | $3.31 | +1,712.69% | 1 | Mar 3, 2023 | |
| CETX Cemtrex | Maintains: Buy | $7.62 → $22 | $0.21 | +10,138.43% | 1 | Feb 6, 2023 | |
| GNPX Genprex | Initiates: Buy | $120 | $1.97 | +5,991.37% | 1 | Jan 30, 2023 | |
| ZOM Zomedica | Initiates: Buy | $6 | $0.15 | +4,037.93% | 1 | Jan 6, 2023 | |
| BCDA BioCardia | Downgrades: Neutral | n/a | $2.94 | - | 2 | Nov 11, 2022 | |
| ADTX Aditxt | Downgrades: Neutral | n/a | $1.47 | - | 1 | Sep 16, 2022 | |
| SMFL Smart for Life | Initiates: Buy | $25,200 | $2.80 | +899,900.00% | 1 | Aug 29, 2022 | |
| DYAI Dyadic International | Downgrades: Neutral | n/a | $1.45 | - | 1 | Jul 18, 2022 | |
| KTRA Kintara Therapeutics | Downgrades: Neutral | n/a | $0.26 | - | 1 | May 16, 2022 | |
| PRPH ProPhase Labs | Downgrades: Neutral | n/a | $3.80 | - | 1 | Oct 13, 2021 | |
| CHEK Check-Cap | Downgrades: Neutral | n/a | $2.01 | - | 1 | Mar 17, 2021 | |
| SNGX Soligenix | Downgrades: Neutral | $720 → $480 | $2.27 | +21,045.37% | 2 | Jul 28, 2020 | |
| CHRS Coherus BioSciences | Initiates: Buy | n/a | $1.39 | - | 3 | Aug 28, 2018 | |
| MNKD MannKind | Terminates: Sell | n/a | $5.03 | - | 3 | Jun 15, 2018 | |
| SNOA Sonoma Pharmaceuticals | Downgrades: Hold | n/a | $0.23 | - | 2 | Mar 6, 2018 | |
| BCLI Brainstorm Cell Therapeutics | Maintains: Buy | n/a | $0.35 | - | 1 | Aug 17, 2017 | |
| IDXG Interpace Biosciences | Initiates: Buy | n/a | $1.10 | - | 1 | Aug 15, 2017 | |
| BLRX BioLineRx | Upgrades: Buy | n/a | $0.53 | - | 1 | May 18, 2017 |
Tonix Pharmaceuticals Holding
Feb 28, 2024
Initiates: Buy
Price Target: $96
Current: $0.74
Upside: +12,925.78%
Bluejay Diagnostics
Aug 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $0.65
Upside: -
GeoVax Labs
Mar 3, 2023
Initiates: Buy
Price Target: $60
Current: $3.31
Upside: +1,712.69%
Cemtrex
Feb 6, 2023
Maintains: Buy
Price Target: $7.62 → $22
Current: $0.21
Upside: +10,138.43%
Genprex
Jan 30, 2023
Initiates: Buy
Price Target: $120
Current: $1.97
Upside: +5,991.37%
Zomedica
Jan 6, 2023
Initiates: Buy
Price Target: $6
Current: $0.15
Upside: +4,037.93%
BioCardia
Nov 11, 2022
Downgrades: Neutral
Price Target: n/a
Current: $2.94
Upside: -
Aditxt
Sep 16, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.47
Upside: -
Smart for Life
Aug 29, 2022
Initiates: Buy
Price Target: $25,200
Current: $2.80
Upside: +899,900.00%
Dyadic International
Jul 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.45
Upside: -
Kintara Therapeutics
May 16, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.26
Upside: -
ProPhase Labs
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.80
Upside: -
Check-Cap
Mar 17, 2021
Downgrades: Neutral
Price Target: n/a
Current: $2.01
Upside: -
Soligenix
Jul 28, 2020
Downgrades: Neutral
Price Target: $720 → $480
Current: $2.27
Upside: +21,045.37%
Coherus BioSciences
Aug 28, 2018
Initiates: Buy
Price Target: n/a
Current: $1.39
Upside: -
MannKind
Jun 15, 2018
Terminates: Sell
Price Target: n/a
Current: $5.03
Upside: -
Sonoma Pharmaceuticals
Mar 6, 2018
Downgrades: Hold
Price Target: n/a
Current: $0.23
Upside: -
Brainstorm Cell Therapeutics
Aug 17, 2017
Maintains: Buy
Price Target: n/a
Current: $0.35
Upside: -
Interpace Biosciences
Aug 15, 2017
Initiates: Buy
Price Target: n/a
Current: $1.10
Upside: -
BioLineRx
May 18, 2017
Upgrades: Buy
Price Target: n/a
Current: $0.53
Upside: -